title: References - Neonatal Intensive Care Drug Manual
text: 1. Vemgal P, Ohlsson A. Interventions for non‐oliguric hyperkalaemia in preterm neonates. Cochrane Database of Systematic Reviews. 2012(5).
  2. Online M. Resonium A Powder for suspension and Calcium resonium powder for suspension. Accessed on 21 January 2021
  3. Hu P-S, Su B-H, Peng C-T, Tsai C-H. Glucose and insulin infusion versus kayexalate for the early treatment of non-oliguric hyperkalemia in very-low-birth-weight infants. Acta Paediatrica Taiwanica. 1999;40(5):314-8.
  4. Malone TA. Glucose and insulin versus cation-exchange resin for the treatment of hyperkalemia in very low birth weight infants. The Journal of pediatrics. 1991;118(1):121-3.
  5. Singh BS, Sadiq HF, Noguchi A, Keenan WJ. Efficacy of albuterol inhalation in treatment of hyperkalemia in premature neonates. The Journal of pediatrics. 2002;141(1):16-20.
  6. Lillemoe K, Romolo J, Hamilton SR, Pennington L, Burdick JF, Williams G. Intestinal necrosis due to sodium polystyrene (Kayexalate) in sorbitol enemas: clinical and experimental support for the hypothesis. Surgery. 1987;101(3):267-72.
  7. Dardik A, Moesinger RC, Efron G, Barbul A, Harrison MG. Acute abdomen with colonic necrosis induced by Kayexalate-sorbitol. Southern medical journal. 2000;93(5):511-3.
  8. Milley JR, Jung AL. Hematochezia associated with the use of hypertonic sodium polystyrene sulfonate enemas in premature infants. Journal of perinatology: official journal of the California Perinatal Association. 1995;15(2):139-42.
  9. Bennett LN, Myers TF, Lambert GH. Cecal perforation associated with sodium polystyrene sulfonate-sorbitol enemas in a 650 gram infant with hyperkalemia. American journal of perinatology. 1996;13(03):167-70.
  10. Grammatikopoulos T, Greenough A, Pallidis C, Davenport M. Benefits and risks of calcium resonium therapy in hyperkalaemic preterm infants. Acta Paediatrica. 2003;92(1):118-20.
  11. Yaseen H, Khalaf M, Dana A, Yaseen N, Darwich M. Salbutamol versus cation-exchange resin (kayexalate) for the treatment of nonoliguric hyperkalemia in preterm infants. Am J Perinatol. 2008;25(3):193-7.
  |